What is the 13F Pro Quality Score for CTSO?

13F Pro ranks Cytosorbents Corp (CTSO) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View CTSO's current score at https://13fpro.ai/research/CTSO (free sign-up required for the full ranking).

Which hedge funds own the most CTSO stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of CTSO include AVENIR, VANGUARD CAPITAL MANAGEMENT, Skylands Capital,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/CTSO as soon as new 13F filings post.

Where does 13F Pro source CTSO data?

All Cytosorbents Corp fundamentals and ownership data come directly from SEC EDGAR. Cytosorbents Corp files with the SEC under CIK 1175151. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is CTSO in?

Cytosorbents Corp (CTSO) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is CTSO research updated on 13F Pro?

CTSO's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Cytosorbents Corp(CTSO)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1175151 CTSO stock profile & AI dashboard →

13F Pro Quality Score

19.5/100

Rank #2,691 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

32.5/100

Profitability

18.2/100

Balance Sheet

12.7/100

Earnings Quality

30.0/100

Free Cash Flow

13.0/100

Institutional Flow

33.7/100

Revenue Scale

8.7/100

Dilution Risk

20.7/100

CTSO Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Cytosorbents Corp (CTSO), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores CTSO at 19.5/100 on a 32-signal composite quality model, placing it at rank #2,691 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include revenue scale (8.7) and balance sheet strength (12.7), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Cytosorbents Corp reports quarterly revenue of $8.9M, net income of $-5.1M, an operating margin of -34.3%. Top institutional holders of CTSO by reported 13-F value include AVENIR, VANGUARD CAPITAL MANAGEMENT, Skylands Capital,, based on the most recent SEC filings. CTSO trades on the Nasdaq exchange and files with the SEC under CIK 1175151. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CTSO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cytosorbents Corp directly from SEC EDGAR. Cytosorbents Corp's 13F Pro composite quality score has ranged between 11 and 22 since 2024, currently 19.5 — an improving long-term trajectory across 16 quarterly and live scoring snapshots.

✦

Fun facts about Cytosorbents Corp

Quirks, history, and lore behind CTSO — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. medical technology company · small-cap · listed on Nasdaq · headquartered in New Jersey.
2
The Numbers
Annual revenue in the range of $30–40 million — not exactly a pharma titan — with most sales driven by a single flagship product used in hospital critical care settings.
3
The History
Founded in the early 2000s, the company spun out of academic research into blood purification technology and spent years navigating FDA approval pathways before gaining commercial traction.
4
The Secret
Its core technology works by adsorbing cytokines and inflammatory mediators directly from the bloodstream — essentially a tiny bouncer that yanks dangerous proteins out of circulation.
5
The Lore
Its device gained significant attention during COVID-19 as hospitals explored treatments for the deadly cytokine storm that killed critically ill patients, sparking a wave of emergency use interest.
6
The Giveaway
Its CytoSorb cartridge is approved in over 70 countries to filter the blood of sepsis and cardiac surgery patients — a company literally named after what its one device does.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$8.9M

Net Income

Q1 2026

$-5.1M

Free Cash Flow

Q1 2026

$-1.2M

Operating Margin

Q1 2026

-34.3%

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+4.1% YoY

$37.1MFY 2025

FY22 $34.7MFY23 $31.1MFY24 $35.6MFY25 $37.1M

Net Income

+60.4% YoY

$-8.2MFY 2025

FY22 $-32.8MFY23 $-29.2MFY24 $-20.7MFY25 $-8.2M

Operating Income

+10.4% YoY

$-14.7MFY 2025

FY22 $-31.5MFY23 $-31.9MFY24 $-16.5MFY25 $-14.7M

EPS (Diluted)

+65.8% YoY

$-0.13FY 2025

FY22 $-0.75FY23 $-0.65FY24 $-0.38FY25 $-0.13

Total Assets

-6.7% YoY

$44.2MFY 2025

FY22 $63.2MFY23 $53.0MFY24 $47.4MFY25 $44.2M

Total Debt

+19.1% YoY

$16.7MFY 2025

FY22 $5.0MFY23 $7.5MFY24 $14.0MFY25 $16.7M

Op. Cash Flow

+14.2% YoY

$-12.4MFY 2025

FY22 $-28.2MFY23 $-21.7MFY24 $-14.4MFY25 $-12.4M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$37.1M +4.1%	$35.6M +14.5%	$31.1M -10.4%	$34.7M -19.6%	$43.2M +5.3%	$41.0M
Net Income	$-8.2M +60.4%	$-20.7M +29.2%	$-29.2M +10.9%	$-32.8M -33.6%	$-24.6M -213.4%	$-7.8M
Operating Income	$-14.7M +10.4%	$-16.5M +48.5%	$-31.9M -1.4%	$-31.5M -38.6%	$-22.7M -119.3%	$-10.4M
EPS (Diluted)	$-0.13 +65.8%	$-0.38 +41.5%	$-0.65 +13.3%	$-0.75 -31.6%	$-0.57 -185.0%	$-0.20
Total Assets	$44.2M -6.7%	$47.4M -10.5%	$53.0M -16.3%	$63.2M -29.4%	$89.5M -0.5%	$90.0M
Total Debt	$16.7M +19.1%	$14.0M +85.6%	$7.5M +50.9%	$5.0M	—	$0.00
Operating Cash Flow	$-12.4M +14.2%	$-14.4M +33.4%	$-21.7M +23.3%	$-28.2M -101.6%	$-14.0M -149.5%	$-5.6M

AI Insight: CTSO Financial Trends

Cytosorbents faces acute solvency crisis: debt surged to $24M while equity collapsed to $2M in Q1 2026, amid persistent unprofitability and negative cash generation.

• Revenue has remained flat-to-declining, ranging $7M–$10M over 8 quarters with no growth trajectory evident.

• Net income negative in 6 of 8 quarters; Q2 2025's $2M profit was sole exception; Q1 2026 lost $5M.

• Operating cash flow negative every quarter, totaling ~$23M cumulative burn since Q2 2024.

• Total debt surged 50% from $16M (Q2 2024) to $24M (Q1 2026); equity eroded 88% to $2M.

⚠ Debt-to-equity ratio now >12x; company approaching technical insolvency if losses and debt accumulation continue.

⚠ Operating margin stable around –33% to –50%, indicating business model stress or scale challenges unresolved.

AI Insight: CTSO Ratio Trends

Cytosorbents remains deeply unprofitable across all efficiency metrics, with operating margin worsening to -34.3% in Q1 2026 and ROIC collapsing to -47.2%.

• Operating margin deteriorated from -30.2% in Q3 2025 to -34.3% in Q1 2026, reversing modest improvement seen earlier in 2025.

• Net profit margin swung wildly: positive 20.2% in Q2 2025 to -59.5% in Q4 2025 to -57.9% in Q1 2026, indicating earnings volatility.

• Debt-to-equity ratio spiked to 10.76 by Q1 2026 TTM from 2.82 in Q4 2025, signaling sharply elevated leverage and financial stress.

⚠ ROIC deteriorated to -47.2% in Q1 2026 from -48.5% in Q3 2025; negative ROIC persists across entire dataset, destroying shareholder value.

⚠ Return on assets at -50.6% in Q1 2026 reflects severe operational losses; Q1 typically weak but magnitude warrants capital structure review.

Get alerted when CTSO's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Cytosorbents Corp including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of CTSO

AVENIR CORP
$3.0M5,215,776 sh
VANGUARD CAPITAL MANAGEMENT LLC
$1.1M1,879,989 sh
Skylands Capital, LLC
$967.0K1,707,498 sh
Neuberger Berman Group LLC
$950.8K1,683,007 sh
CM Management, LLC
$836.1K1,476,500 sh
BlackRock, Inc.
$443.4K782,992 sh
GEODE CAPITAL MANAGEMENT, LLC
$400.6K707,262 sh
Sargent Investment Group, LLC
$311.4K549,900 sh
Pathstone Holdings, LLC
$283.1K499,955 sh
VANGUARD FIDUCIARY TRUST CO
$177.6K313,856 sh

Fund	Value	Shares
AVENIR CORP	$3.0M	5,215,776
VANGUARD CAPITAL MANAGEMENT LLC	$1.1M	1,879,989
Skylands Capital, LLC	$967.0K	1,707,498
Neuberger Berman Group LLC	$950.8K	1,683,007
CM Management, LLC	$836.1K	1,476,500
BlackRock, Inc.	$443.4K	782,992
GEODE CAPITAL MANAGEMENT, LLC	$400.6K	707,262
Sargent Investment Group, LLC	$311.4K	549,900
Pathstone Holdings, LLC	$283.1K	499,955
VANGUARD FIDUCIARY TRUST CO	$177.6K	313,856

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put CTSO on your watchlist

Track score changes the day Cytosorbents Corp files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is CTSO a good stock to buy?

13F Pro's AI-powered analysis of Cytosorbents Corp (CTSO) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for CTSO are available on the CTSO stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own CTSO?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling CTSO. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Cytosorbents Corp's investment landscape.